Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $5.67 Consensus PT from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $5.67.

Separately, HC Wainwright reduced their target price on Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 1st.

Insider Buying and Selling at Karyopharm Therapeutics

In other news, CEO Richard A. Paulson sold 80,470 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $94,149.90. Following the sale, the chief executive officer now directly owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Richard A. Paulson sold 80,470 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the sale, the chief executive officer now directly owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Michael Mason sold 27,687 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $32,393.79. Following the transaction, the chief financial officer now directly owns 404,918 shares of the company’s stock, valued at $473,754.06. The disclosure for this sale can be found here. Insiders sold a total of 164,542 shares of company stock worth $198,175 over the last ninety days. Company insiders own 3.32% of the company’s stock.

Institutional Trading of Karyopharm Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Monashee Investment Management LLC acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $115,000. Panagora Asset Management Inc. acquired a new position in Karyopharm Therapeutics during the 4th quarter valued at about $197,000. BNP Paribas Financial Markets raised its position in shares of Karyopharm Therapeutics by 6.5% during the 4th quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after buying an additional 108,286 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $339,000. Finally, Simplicity Solutions LLC bought a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $33,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Trading Down 3.4 %

Shares of NASDAQ:KPTI opened at $1.13 on Friday. The firm has a market cap of $130.03 million, a PE ratio of -0.90 and a beta of 0.03. The company has a fifty day simple moving average of $1.34 and a 200 day simple moving average of $1.05. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $4.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $33.75 million for the quarter, compared to the consensus estimate of $33.50 million. During the same period in the prior year, the firm earned ($0.43) earnings per share. As a group, equities research analysts forecast that Karyopharm Therapeutics will post -1.19 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).